PLCG1

Across TCGA pan-cancer cohorts, PLCG1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLCG1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PLCG1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLCG1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where PLCG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.290	0.572	.015	7	view →
LUAD	DFS	Median	All	0.940	0.687	.019	6	view →
HNSC	DFS	Quartile	III,IV	1.000	0.875	.024	3	view →
PDAC	OS	Median	III,IV	0.245	0.617	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLCG1–GBM (DFS)

Open the GBM breakdown →